Mexican authorities find 11 clandestine graves with 15 bodies near border with GuatemalaDazostinag sodium by Takeda Pharmaceutical for Non-Small Cell Lung Cancer: Likelihood of ApprovalA wind turbine installation vessel built by Hanwha Ocean Hanwha Ocean Co. and another major South Korean shipbuilder have won deals worth a combined 1.4 trillion won ($951 million) to build a wind turbine installation vessel (WTIV) each for unidentified domestic firms. A WTIV is a vessel specifically designed to install offshore wind turbines. It is priced between 700 billion won and 800 billion won. Hanwha and the unidentified Korean shipbuilder have agreed to build a combined two WTIVs – one for an energy company and the other for a construction firm, people familiar with the matter said on Monday. The companies are currently fine-tuning details, including construction conditions, according to sources. Analysts said the deals are seen as a crucial step in safeguarding Korea’s offshore wind turbine construction market, which is at risk of being dominated by Chinese and European companies. Korea plans to expand its offshore wind power generation capacity to 14.3 GW by 2030 from the current 0.13 GW, requiring an addition of 2 GW capacity annually. (Graphics by Dongbeom Yun) LACK OF LARGE WTIVs However, a lack of large WTIVs has left the domestic wind turbine market vulnerable to competition from European and Chinese firms. “Once the two large WTIVs are up and running, Korea will have a competitive edge in the nation’s offshore wind turbine construction market,” said a local shipbuilding industry official. With global warming driving attention to renewable energy sources like offshore wind power, demand for large offshore WTIVs is steadily increasing. Korea is a major in the emerging WTIV market with Hanwha Ocean building four such vessels and Samsung Heavy Industries Co. three, mainly for overseas clients so far. Korean shipbuilders also c ompete to lead the global wind farm industry , an emerging game-changer in the renewable energy sector, which generates power through offshore floating facilities. In Korea, there’s only one WTIV that can build smaller turbines with 5 to 10 MW capacity. Offshore wind turbines With the larger 15 MW turbines becoming the industry standard, Korea could lose the wind turbine market without sufficient WTIV capabilities, industry officials said. Korean shipbuilders specialize in building large WTIVs capable of installing 15 MW turbines, bringing their annual installation capacities to 700–800 MW per vessel. GREATER CLOUT IN WIND POWER MARKET Industry officials said the latest WTIV contracts would lay the foundation for Korean shipbuilders to expand their clout in the domestic offshore wind power market. Korea’s win power market is forecast to grow to grow to 14.3 GW worth some 100 trillion won by 2030 and 26.7 GW worth 182 trillion won by 2036, according to government data. WTIV charter fees from overseas ship owners have increased by 24% over the past year. Industry officials said installing offshore wind turbines involves surveying seabed conditions, which is linked to national security concerns. Write to Yeong-Hyo Jeong, Jung-hwan Hwang and Hyung-Kyu Kim at hugh@hankyung.com In-Soo Nam edited this article.

By MICHELLE L. PRICE and ROB GILLIES NEW YORK (AP) — President-elect Donald Trump’s recent dinner with Canadian Prime Minister Justin Trudeau and his visit to Paris for the reopening of the Notre Dame Cathedral were not just exercises in policy and diplomacy. They were also prime trolling opportunities for Trump. Related Articles National Politics | Trump names Andrew Ferguson as head of Federal Trade Commission to replace Lina Khan National Politics | Biden says he was ‘stupid’ not to put his name on pandemic relief checks like Trump did National Politics | Biden issues veto threat on bill expanding federal judiciary as partisan split emerges National Politics | Trump lawyers and aide hit with 10 additional felony charges in Wisconsin over 2020 fake electors National Politics | After withdrawing as attorney general nominee, Matt Gaetz lands a talk show on OANN television Throughout his first term in the White House and during his campaign to return, Trump has spun out countless provocative, antagonizing and mocking statements. There were his belittling nicknames for political opponents, his impressions of other political figures and the plentiful memes he shared on social media. Now that’s he’s preparing to return to the Oval Office, Trump is back at it, and his trolling is attracting more attention — and eyerolls. On Sunday, Trump turned a photo of himself seated near a smiling first lady Jill Biden at the Notre Dame ceremony into a social media promo for his new perfume and cologne line, with the tag line, “A fragrance your enemies can’t resist!” The first lady’s office declined to comment. When Trudeau hastily flew to Florida to meet with Trump last month over the president-elect’s threat to impose a 25% tax on all Canadian products entering the U.S., the Republican tossed out the idea that Canada become the 51st U.S. state. The Canadians passed off the comment as a joke, but Trump has continued to play up the dig, including in a post Tuesday morning on his social media network referring to the prime minister as “Governor Justin Trudeau of the Great State of Canada.” After decades as an entertainer and tabloid fixture, Trump has a flair for the provocative that is aimed at attracting attention and, in his most recent incarnation as a politician, mobilizing fans. He has long relished poking at his opponents, both to demean and minimize them and to delight supporters who share his irreverent comments and posts widely online and cheer for them in person. Trump, to the joy of his fans, first publicly needled Canada on his social media network a week ago when he posted an AI-generated image that showed him standing on a mountain with a Canadian flag next to him and the caption “Oh Canada!” After his latest post, Canadian Immigration Minister Marc Miller said Tuesday: “It sounds like we’re living in a episode of South Park.” Trudeau said earlier this week that when it comes to Trump, “his approach will often be to challenge people, to destabilize a negotiating partner, to offer uncertainty and even sometimes a bit of chaos into the well established hallways of democracies and institutions and one of the most important things for us to do is not to freak out, not to panic.” Even Thanksgiving dinner isn’t a trolling-free zone for Trump’s adversaries. On Thanksgiving Day, Trump posted a movie clip from “National Lampoon’s Christmas Vacation” with President Joe Biden and other Democrats’ faces superimposed on the characters in a spoof of the turkey-carving scene. The video shows Trump appearing to explode out of the turkey in a swirl of purple sparks, with the former president stiffly dancing to one of his favorite songs, Village People’s “Y.M.C.A.” In his most recent presidential campaign, Trump mocked Florida Gov. Ron DeSantis, refusing to call his GOP primary opponent by his real name and instead dubbing him “Ron DeSanctimonious.” He added, for good measure, in a post on his Truth Social network: “I will never call Ron DeSanctimonious ‘Meatball’ Ron, as the Fake News is insisting I will.” As he campaigned against Biden, Trump taunted him in online posts and with comments and impressions at his rallies, deriding the president over his intellect, his walk, his golf game and even his beach body. After Vice President Kamala Harris took over Biden’s spot as the Democratic nominee, Trump repeatedly suggested she never worked at McDonalds while in college. Trump, true to form, turned his mocking into a spectacle by appearing at a Pennsylvania McDonalds in October, when he manned the fries station and held an impromptu news conference from the restaurant drive-thru. Trump’s team thinks people should get a sense of humor. “President Trump is a master at messaging and he’s always relatable to the average person, whereas many media members take themselves too seriously and have no concept of anything else other than suffering from Trump Derangement Syndrome,” said Steven Cheung, Trump’s communications director. “President Trump will Make America Great Again and we are getting back to a sense of optimism after a tumultuous four years.” Though both the Biden and Harris campaigns created and shared memes and launched other stunts to respond to Trump’s taunts, so far America’s neighbors to the north are not taking the bait. “I don’t think we should necessarily look on Truth Social for public policy,” Miller said. Gerald Butts, a former top adviser to Trudeau and a close friend, said Trump brought up the 51st state line to Trudeau repeatedly during Trump’s first term in office. “Oh God,” Butts said Tuesday, “At least a half dozen times.” “This is who he is and what he does. He’s trying to destabilize everybody and make people anxious,” Butts said. “He’s trying to get people on the defensive and anxious and therefore willing to do things they wouldn’t otherwise entertain if they had their wits about them. I don’t know why anybody is surprised by it.” Gillies reported from Toronto. Associated Press writer Darlene Superville contributed to this report.

The recently revealed trailer offers a glimpse into the stunning visuals and epic battles that await audiences in the movie. From the intricate details of the characters' designs to the vibrant colors of the world they inhabit, every frame of the trailer showcases the exceptional artistry and craftsmanship that fans have come to expect from the Demon Slayer series.Getting smart about car insurance can provide cost savings and peace of mind

An abandoned runway at Syracuse Hancock International Airport (SYR) is about to get a new lease on life, following Micron Technologies' plans to use the area for a parking lot. A new life for runway 6/24 Syracuse International Airport is located five miles from the city's downtown core and is currently operated by the Syracuse Regional Airport Authority. The airport has two active runways: 10/28 (9,003 feet) and 15/33 (7,500 feet). However, a third was abandoned over five decades ago and has never been covered ( runway 6/24). Micron Technology Inc. is planning to build a new large semiconductor plant in the neighboring area of Clay. During construction, hundreds of staff will need parking space. Micron plans to use shuttle buses to transport construction workers between the airport runway parking lot and White Pine Commerce Park, where their factory is being developed. They have signed a lease for the runway for up to five years. Micon Technology, which manufactures memory chips, announced that it had selected the area of Clay for a semiconductor fabrication facility. The development is expected to cost up to $100 billion and establish around 50,000 jobs over a 20-year lifespan. With such development, the airport expects cargo traffic to increase by almost triple. In total, over 16 commercial airports serve the state. Have you heard the Simple Flying podcast recently? Preparing for increased traffic volumes at SYR Syracuse Hancock International Airport is already planning for increased traffic, with a long-term plan to expand the current airport terminal and develop a larger parking garage. Micron intends to commence construction on its 1,400-acre site on Caughdenoy Road and Route 31 next year. Using the abandoned runway will add around 1,700 to 2,000 extra parking spaces for construction workers. To ensure efficiency of use for the abandoned runway, Micron will be paying for parking stripes to be painted on the runway and, as already noted, will provide shuttle buses to and from the location during construction. The old runway is one of three at the airport and extends to 5,500 feet. It was built by the United States Army Air Forces in 1942 and, during World War II, was also a storage base for the B-17 and B-24 bombers . It was eventually retired when the city took possession of the airport, and the area was being intersected by Interstate 81. Two of the most notable aircraft in the World War II era. Simple Flying reached out to Syracuse Hancock International Airport to comment on the creative new use of the abandoned runway. However, they had not responded by the time this article was published. We will update this article when we receive a response. Get all the latest aviation news for North America here Airlines serving Syracuse According to FAA enplanement records , excluding airports serving New York City, Syracuse is one of the busiest airports in New York State (after Buffalo, Albany, and Rochester). Current airport operators include Allegiant, American, Breeze, Delta Air Lines, Frontier, JetBlue, Sun Country, and United Airlines . Three cargo carriers also serve the airport, with operations by Quest Diagnostics, FedEx Express , and UPS Airlines. NOTAMs reportedly indicated that the runway was undergoing routine maintenance.

Phase 3 Study Results Demonstrated Three Year, Disease-Free Survival of 96% THOUSAND OAKS, Calif. , Dec. 7, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data demonstrating that adding BLINCYTO ® (blinatumomab) to chemotherapy significantly improves disease-free survival (DFS) in newly diagnosed pediatric patients with National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL) of average or higher risk of relapse. The data are from a Phase 3 study (AALL1731) conducted by the Children's Oncology Group. The results were simultaneously published in the New England Journal of Medicine and will be presented during the plenary session on Sunday, Dec. 8 , at 2 p.m. PT at the 66 th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego . "Over the last decade, BLINCYTO has reshaped the treatment landscape for B-ALL, offering a critical lifeline for thousands of adult and pediatric patients," said Jay Bradner , M.D., executive vice president of Research and Development and chief scientific officer at Amgen. "These powerful new data leave us little doubt about the profound impact of this medicine for a large number of children affected by this disease. We are grateful to the Children's Oncology Group, along with the patients, families and clinical teams, for their dedication and partnership in advancing this critical study to improve the lives of children with cancer." Based on the results of the first pre-specified interim analysis for efficacy, the study met its primary endpoint of DFS and study randomization was terminated early based on the recommendation from the data and safety monitoring committee due to the benefit observed in the BLINCYTO arm compared to the chemotherapy-only arm. Overall, the 3-year DFS was 96.0% for patients treated with chemotherapy plus BLINCYTO compared to 87.9% for those treated with only chemotherapy. The hazard ratio (HR) was 0.39 [95% confidence interval (CI) 0.24-0.64], indicating a 61% reduction in the risk of disease relapse, secondary malignant neoplasm or remission death with BLINCYTO. At 3 years, more patients remained alive and cancer free when treated with BLINCYTO plus chemotherapy compared to chemotherapy alone. "The AALL1731 study results are truly practice-changing, further solidifying blinatumomab's role as the standard of care for a large number of children with B-ALL," said Sumit Gupta , M.D., Ph.D., FRCPC, co-chair of the Children's Oncology Group AALL1731 study and oncologist and clinician investigator, Division of Haematology/Oncology at The Hospital for Sick Children (SickKids) and associate professor of pediatrics at the University of Toronto . "These breakthrough data showing a significant improvement in disease-free survival are poised to bring substantial clinical value to children with newly diagnosed B-ALL." The addition of BLINCYTO to chemotherapy in standard risk patients resulted in outcomes similar to those previously achieved in only the most favorable pediatric risk subsets. Among SR-Average patients, 3-year DFS was 97.5% for patients treated with BLINCYTO compared to 90.2% for those treated with only chemotherapy (HR 0.33, CI 0.15-0.69). For SR-High patients, 3-year DFS was 94.1% for those treated with BLINCYTO compared to 84.8% for those treated with only chemotherapy (HR 0.45, 95% CI 0.24-0.85). "Relapsed ALL remains a major cause of pediatric cancer mortality, with nearly half of the relapses occurring in children with standard-risk B-ALL," said Rachel E. Rau , M.D., co-chair of the Children's Oncology Group AALL1731 study, pediatric hematologist-oncologist at Seattle Children's Hospital and associate professor of pediatrics at the University of Washington . "These findings underscore the progress made with blinatumomab in preventing relapse and support its role as a critical addition to current therapeutic strategies." Safety results are consistent with the known safety profile of BLINCYTO. BLINCYTO has demonstrated a positive balance of benefits and risks, with only 0.3% of first courses associated with Grade 3+ cytokine release syndrome (CRS) and 0.7% with seizures. A higher risk of infections was observed in the BLINCYTO arm. These results provide the first evidence supporting BLINCYTO for use in the consolidation phase in newly diagnosed pediatric Philadelphia chromosome-negative (Ph-) B-ALL patients. This groundbreaking first-in-class Bispecific T-cell Engager (BiTE ® ) therapy is now backed by additional evidence reinforcing its role in redefining a standard of care for both adult and pediatric patients, starting from one month old, regardless of measurable residual disease (MRD) status. The findings further establish BLINCYTO as a versatile first-line consolidation therapy across all ages and treatment backbones. The NCI's Cancer Therapy Evaluation Program (CTEP), which sponsored the study will share data with the U.S. Food and Drug Administration as part of their ongoing communications relating to the trial. About The Children's Oncology Group The Children's Oncology Group (childrensoncologygroup.org), a member of the NCI National Clinical Trials Network (NCTN), is the world's largest organization devoted exclusively to childhood and adolescent cancer research. The Children's Oncology Group unites over 10,000 experts in childhood cancer at more than 200 leading children's hospitals, universities and cancer centers across North America , Australia , New Zealand and Saudi Arabia in the fight against childhood cancer. Today, more than 80% of the 15,000 children and adolescents diagnosed with cancer each year in the United States are cared for at Children's Oncology Group member institutions. Research performed by Children's Oncology Group institutions over the past 50 years has transformed childhood cancer from a virtually incurable disease to one with a combined 5-year survival rate of 86%. The Children's Oncology Group's mission is to improve the cure rate and outcomes for all children with cancer. About AALL1731 (NCT03914625) The AALL1731 study was a Phase 3 randomized trial to determine if two non-sequential cycles of BLINCYTO added to chemotherapy improved disease-free survival (DFS) in children with newly diagnosed pediatric National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL). The study enrolled 4,264 newly diagnosed NCI SR B-ALL patients, of whom 2,334 were risk stratified at the end of induction therapy as either SR-Average or SR-High. At the first planned interim efficacy analysis (data cutoff June 30, 2024 ), 1,440 of the eligible and evaluable patients had been randomized. The AALL1731 study was designed and conducted independently from industry. The Cancer Therapy Evaluation Program (CTEP) of the NCI sponsored the trial and provided funding to the Children's Oncology Group to conduct the study. NCI is part of the National Institutes of Health (NIH). In addition, Amgen provided BLINCYTO and support through an NCI Cooperative Research and Development Agreement. About Acute Lymphoblastic Leukemia (ALL) ALL, also known as acute lymphoblastic leukemia, is a fast-growing type of blood cancer that develops in the bone marrow and can sometimes spread to other parts of the body, including the lymph nodes, liver, spleen and central nervous system. ALL is a rare disease, with an estimated 6,550 new cases, affecting both children and adults, diagnosed in the U.S. in 2024. 1 B-ALL begins in immature cells that would normally develop into B-cell lymphocytes, which are white blood cells that grow in bone marrow. 2,3 B-ALL is the most common type of ALL, constituting approximately 75% of cases in adults and approximately 88% in children, the most common cancer in children. 4,5 About BLINCYTO ® (blinatumomab) BLINCYTO is the first globally approved Bispecific T-cell Engager (BiTE ® ) immuno-oncology therapy that targets CD19 surface antigens on B cells. BiTE ® molecules fight cancer by helping the body's immune system detect and target malignant cells by engaging T cells (a type of white blood cell capable of killing other cells perceived as threats) to cancer cells. By bringing T cells near cancer cells, the T cells can inject toxins and trigger cancer cell death (apoptosis). BiTE ® immuno-oncology therapies are currently being investigated for their potential to treat a wide variety of cancers. BLINCYTO was granted Breakthrough Therapy and Priority Review designations by the U.S. FDA and is approved in the U.S. for the treatment of: In the European Union (EU), BLINCYTO is indicated as monotherapy for the treatment of: BLINCYTO ® IMPORTANT SAFETY INFORMATION WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGICAL TOXICITIES including IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME Contraindications BLINCYTO ® is contraindicated in patients with a known hypersensitivity to blinatumomab or to any component of the product formulation. Warnings and Precautions Adverse Reactions Dosage and Administration Guidelines INDICATIONS BLINCYTO ® (blinatumomab) is indicated for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients one month and older with: Please see BLINCYTO ® full Prescribing Information , including BOXED WARNINGS. About Bispecific T-Cell Engager (BiTE ® ) Technology BiTE technology is a targeted immuno-oncology platform that is designed to engage a patient's own T cells to any tumor-specific antigen, activating the cytotoxic potential of T cells to eliminate detectable cancer. The BiTE immuno-oncology platform has the potential to treat different cancer types through tumor-specific antigens. The BiTE platform has a goal of leading to off-the-shelf solutions, which have the potential to make innovative T-cell treatment available to all providers when their patients need it. For more than a decade, Amgen has been advancing this innovative technology, which has demonstrated strong efficacy in hematological malignancies and now a solid tumor with the approval of IMDELLTRA. Amgen remains committed to progressing multiple BiTE molecules across a broad range of hematologic and solid tumor malignancies, paving the way for additional applications in more tumor types. Amgen is further investigating BiTE technology with the goal of enhancing patient experience and therapeutic potential. To learn more about BiTE technology, visit BiTE ® Technology 101 . About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. For more information, visit Amgen.com and follow Amgen on X , LinkedIn , Instagram , TikTok , YouTube and Threads . Amgen Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla ® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), Amgen's acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on Amgen's acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on Amgen's business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including its most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those Amgen projects. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for Amgen to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and Amgen expects similar variability in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints Amgen has selected. Amgen develops product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as Amgen may have believed at the time of entering into such relationship. Also, Amgen or others could identify safety, side effects or manufacturing problems with its products, including its devices, after they are on the market. Amgen's results may be affected by its ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing its products and global economic conditions. In addition, sales of Amgen's products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, Amgen's research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Amgen's business may be impacted by government investigations, litigation and product liability claims. In addition, Amgen's business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If Amgen fails to meet the compliance obligations in the corporate integrity agreement between Amgen and the U.S. government, Amgen could become subject to significant sanctions. Further, while Amgen routinely obtains patents for its products and technology, the protection offered by its patents and patent applications may be challenged, invalidated or circumvented by its competitors, or Amgen may fail to prevail in present and future intellectual property litigation. Amgen performs a substantial amount of its commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depends on third parties for a portion of its manufacturing activities, and limits on supply may constrain sales of certain of its current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for Amgen's manufacturing activities, the distribution of Amgen's products, the commercialization of Amgen's product candidates, and Amgen's clinical trial operations, and any such events may have a material adverse effect on Amgen's product development, product sales, business and results of operations. Amgen relies on collaborations with third parties for the development of some of its product candidates and for the commercialization and sales of some of its commercial products. In addition, Amgen competes with other companies with respect to many of its marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts for Amgen's products are supplied by sole third-party suppliers. Certain of Amgen's distributors, customers and payers have substantial purchasing leverage in their dealings with Amgen. The discovery of significant problems with a product similar to one of Amgen's products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on its business and results of operations. Amgen's efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology Amgen has acquired, may not be successful. There can be no guarantee that Amgen will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. Amgen may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of Amgen's information technology systems could compromise the confidentiality, integrity and availability of Amgen's systems and Amgen's data. Amgen's stock price may be volatile and may be affected by a number of events. Amgen's business and operations may be negatively affected by the failure, or perceived failure, of achieving its environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect Amgen's business and operations. Global economic conditions may magnify certain risks that affect Amgen's business. Amgen's business performance could affect or limit the ability of the Amgen Board of Directors to declare a dividend or its ability to pay a dividend or repurchase its common stock. Amgen may not be able to access the capital and credit markets on terms that are favorable to it, or at all. Any scientific information discussed in this news release relating to new indications for Amgen's products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) References View original content to download multimedia: https://www.prnewswire.com/news-releases/blincyto-blinatumomab-added-to-chemotherapy-significantly-improves-survival-in-newly-diagnosed-pediatric-patients-with-b-cell-precursor-acute-lymphoblastic-leukemia-b-all-302325381.html SOURCE Amgen

Furthermore, the "Peace of Mind Services" plan includes a focus on safety and security, with AMAP introducing new measures to protect users' personal information and ensure the reliability of the services offered on the platform. This commitment to data security and user privacy is essential in building trust among users and maintaining AMAP's reputation as a trustworthy and reliable service provider.Citigroup Forecasts Strong Price Appreciation for Dollar Tree (NASDAQ:DLTR) StockThe last 16 fixtures of Spires 5-Aside Street Soccer Tournament kicked off on a blistering note yesterday at the Prestigious Stable Football Pitch, Surulere, Lagos. The opening matches saw fans going wide with excitement as the players put up fine football artistry. Results recorded so far show Zion FC lost 2-4 to 2 Odds FC, Yahweh FC defeating Peckings 4-3, Toprocks FC 5-3 better over ASD Academy while VVD FC trounced Owibesebe FC 4 -2. The opening fixtures was witnessed by several football personalities, among whom was the CEO of Spires Media, Dr Femi Bankole-Alibay, the organisers of the tournament. Dr Bankole-Alibay had this to say. “I am excited with what I am seeing today, the turn out and the excitement created around this tournament. “The overall aim of the SPIRES 5-Aside tournament is to unearth talents on the streets of Lagos not captured by the various football academies. “With what I am seeing today, the future of this tournament looks great. We are here to redefine Street Soccer in Nigeria as well as harnessing the immense talents within the Lagos communities,” he added Dr Alibay further revealed that the winner of this season’s tournament will pocket the sum of 5 million naira in prize money while the runners up and the third placed teams will smile home with 3 and 1 million Naira respectively. There are also handsome prizes for the Most Valuable Player (MVP), the best goalkeeper and Coach of the Tournament The tournament runs from November 20 to December 7, 2024.

Lebawit Lily Girma | (TNS) Bloomberg News When winter rolls around, travelers predictably turn their attention to beaches. And this year, it’s the destination that comedian Tony Hinchcliffe called “a floating island of garbage in the middle of the ocean” that’s experiencing outsize demand from Americans planning a warm island vacation. Talk about trashing stereotypes. Related Articles Travel | Would you pay $700 a night to sleep under the stars at this Colorado resort? Travel | Thailand’s starring role in ‘The White Lotus’ is about to pay off Travel | 5 under-the-radar travel destinations the UN says you should visit Travel | Gift ideas for people planning their next trip Travel | Nayarit, in Mexico, is home to nine ‘magical’ towns and more Puerto Rico has recovered overseas visitors (excluding those from Canada and Mexico) faster than any U.S. state or territory — a staggering 85% increase over its 2019 overseas inbound visitor levels as of 2023, according to an October study from the U.S. National Travel and Tourism Office. There are now more daily flights from the U.S. West Coast, and hotel bookings are 6% higher so far in this last quarter of 2024 year-over-year. It’s a trifecta of tourism growth: more visitors, but also longer stays and a higher spend that reached a record $9.8 billion in 2023, boosting small businesses as well as major brands. “We don’t have a slow season in Puerto Rico anymore,” says Brad Dean, chief executive officer at Discover Puerto Rico. Even if they’re not booking, people are dreaming about “La Isla.” By tracking flight searches for trips between November 2024 and February 2025, a measure of “inspirational” demand, tourism intelligence company Mabrian Technologies reports Puerto Rico is up 9% compared with the same period last year and leads Barbados, the Dominican Republic, Jamaica and the Bahamas in the Caribbean proper. Only Costa Rica ranked higher in the wider region. Dean attributes Puerto Rico’s ongoing tourism growth to a strategic effort to reposition the island’s brand as more than a sun-and-sea destination, starting back in 2018. That led to the Live Boricua campaign, which began in 2022 and leaned heavily on culture, history and cuisine and was, Dean says, “a pretty bold departure” in the way Puerto Rico was showcased to travelers. He adds that at least $2 billion in tourism spend is linked to this campaign. “We (also) haven’t shied away from actively embracing the LGBTQ+ community, and that has opened up Puerto Rico to audiences that may not have considered the Caribbean before,” Dean says. Hotels are preparing to meet this growing demand: A number of established boutique properties are undergoing upgrades valued between $4 million and more than $50 million, including Hotel El Convento; La Concha, which will join the Marriott Autograph Collection; Condado Vanderbilt Hotel; and the Wyndham Grand Rio Mar. That’s in addition to ultra-chic options that are coming online in 2025, including the adults-only Alma San Juan, with rooms overlooking Plaza Colón in the heart of Old San Juan, and the five-star Veranó boutique hotel in San Juan’s trendy Santurce neighborhood. The beachfront Ritz-Carlton San Juan in Isla Verde will also be reopening seven years after Hurricane Maria decimated the island. The travel industry’s success is helping boost employment on the island, to the tune of 101,000 leisure and hospitality jobs as of September 2024, a 26% increase over pre-pandemic levels, according to the U.S. Bureau of Labor Statistics. Efforts to promote Puerto Rico’s provinces beyond the San Juan metro area — such as surfing hub Rincón on the west coast, historical Ponce on the south coast and Orocovis for nature and coffee haciendas in the central mountains —have spread the demand to small businesses previously ignored by the travel industry. Take Sheila Osorio, who leads workshops on Afro-Puerto Rican bomba music and dance at Taller Nzambi, in the town of Loíza, 15 miles east of San Juan; or Wanda Otero, founder of cheese-producing company Vaca Negra in Hatillo, an hour’s drive west of Old San Juan, where you can join a cheese-making workshop and indulge in artisanal cheese tastings. “The list of businesses involved in tourism has gone from 650 in 2018 to 6,100, many of which are artists and artisans,” Dean says. While New Yorkers and Miami residents have always been the largest visitor demographic, Dean says more mainland Americans now realize that going to Puerto Rico means passport-free travel to enjoy beaches, as well as opportunities to dine in Michelin-rated restaurants, hike the only rainforest in the U.S. and kayak in a bioluminescent bay. Visitors from Chicago and Dallas, for example, have increased by approximately 40% from July 1, 2023, to June 30, 2024, compared with the same period in 2022-2023, and more travelers are expected from Denver now that United Airlines Holdings Inc. has kicked off its first nonstop service to San Juan, beginning on Oct. 29. Previously, beach destinations that were easy to reach on direct flights from Denver included Mexico, Belize and California, but now Puerto Rico joins that list with a 5.5-hour nonstop route that cuts more than two hours from the next-best option. Given United Airlines’ hub in San Francisco, it could mean more travelers from the Golden State in the near future, too. In December, U.S. airlines will have 3,000 more seats per day to the territory compared with the same period last year, for a total of 84,731 — surpassing even Mexico and the Dominican Republic in air capacity, according to data from aviation analytics firm Cirium. Luis Muñoz Marín International Airport, the island’s primary gateway, is projecting a record volume of 13 million passengers by year’s end — far surpassing the 9.4 million it saw in 2019. As for Hinchcliffe’s “floating island of garbage” line, Dean says it was “a terribly insensitive attempt at humor” that transformed outrage into a marketing silver lining, with an outpouring of positive public sentiment and content on Puerto Rico all over social media. Success, as that old chestnut goes, may be the best revenge. “It was probably the most efficient influencer campaign we’ve ever had,” Dean says, “a groundswell of visitors who posted their photos and videos and said, ‘This is the Puerto Rico that I know.’” ©2024 Bloomberg L.P. Visit bloomberg.com. Distributed by Tribune Content Agency, LLC.The process of creating the hairstyle was a sight to behold. Xiao Hua meticulously worked with various tools and products, showcasing her artistry and attention to detail. From precision cutting to strategic color placement, every step was executed with precision and care. As Xiang Zuo sat patiently in the stylist's chair, the anticipation in the room was palpable.Tencent Video's decision to implement these membership adjustments reflects a strategic move to attract new users and stay competitive in the online streaming market. By offering exclusive perks and personalized recommendations, the platform aims to enhance user engagement and satisfaction. However, the different treatment of new and old users has triggered a debate about fairness and transparency in membership policies.

BUFFALO — The year started with a bang. In January, Gov. Kathy Hochul named UB the home of Empire AI, a new $400 million supercomputing center that will provide UB and partners with breathtakingly powerful resources to harness artificial intelligence for the betterment of society. An avalanche of advancements – all pointing towards UB’s leadership in AI, in New York State and nationwide – followed the governor’s announcement. With interest in AI surging globally, these advancements showcase and build upon UB’s impressive half-century of expertise in AI research and education. They also hint at a brighter future, where AI’s uncanny abilities merge with human ingenuity to tackle society’s greatest challenges. “Traditionally, colleges and universities are at the epicenter of life-changing research and ideas,” said Venu Govindaraju, vice president for research and economic development. “The University at Buffalo is pushing the boundaries of artificial intelligence and data science in fields that are critical to the state’s and nation’s future.” As 2024 comes to a close, here’s a look back at what has been a year of AI at UB. January UB researchers have been laying the groundwork for today’s boom in artificial intelligence for decades. This includes pioneering work creating the world’s first autonomous handwriting recognition system, which the U.S. Postal Service and Royal Mail adopted to save billions of dollars. Those innovations explain, in part, why Gov. Kathy Hochul chose UB to be the home of Empire AI, a consortium of public and private universities, and foundations, that will harness AI for the public good while driving economic development. “We want to make sure New York State is the capital of AI development ... but I need a home for this supercomputer that’ll power the innovation all over our state. And I’m proud to announce that the home will be right here at [UB],” Hochul said Jan. 26 at the Center for the Arts. Earlier in the month, during her State of the State address in Albany, the governor spotlighted UB student Holliday Sims for her work using AI to improve the child welfare system. February UB was chosen to join the federal government’s first-ever consortium dedicated to ensuring that AI systems are safe and trustworthy. Announced Feb. 8, the U.S. AI Safety Institute Consortium (AISIC) includes government agencies and top research universities, as well as Microsoft, Apple, Google, OpenAI and other tech companies. AISIC will create standards for AI usage that protect Americans’ privacy; advance equity and civil rights; and promote innovation and competition. Weeks later, UB was among 28 new members to join AI Alliance, an international coalition led by IBM and Meta that is dedicated to promoting open, safe and responsible AI. March On a beautiful spring day, engineering professor Chase Murray and students took to the skies at UB’s Structure for Outdoor Autonomy Research, one of the largest outdoor drone-testing labs among the nation’s colleges and universities. Murray uses AI and other technologies to optimize how autonomous vehicles work together – research that has implications in logistics, search-and-rescue, surveillance and more. Elsewhere, researchers in UB’s Institute for Artificial Intelligence and Data Science kept tabs on their AI system that aims to improve indoor farming and address food insecurity. And another research group began using AI to make algae fuel production more cost-effective. The projects illustrate UB’s commitment to sustainability and social justice. April April brought Senate Majority Leader Charles Schumer and Sethuraman Panchanathan, director of the National Science Foundation, to campus. The occasion? “Today, we’re here to celebrate something truly amazing: the opening of the new, $20 million, federally funded National AI Institute for Exceptional Education, and it’s going to be housed right here at UB,” said Schumer. Funded by the NSF and Department of Education, the institute will create AI systems that ensure children with speech and language disorders receive timely, effective assistance. The work, which addresses the nationwide shortage of speech-language pathologists, will help ensure that millions of children do not fall behind in their academic and socio-emotional development. May On May 31, UB hosted thought leaders from IBM, M&T Bank, Moog and other institutions for its ongoing chat series on AI and society. “Don’t be an AI user, be an AI value creator,” Dario Gil, IBM senior vice president and director of research, told attendees at the Center of Excellence in Bioinformatics and Life Sciences. The event included presentations from UB researchers using AI to make advancements in medicine, medical devices, climate change, materials science, pharmaceutical science and other fields. June An electricity grid that uses AI to identify and fix problems before they cause widespread power outages? It could become reality sooner than you think due to research published June 4 and co-led by Souma Chowdhury, who studies how to apply AI to complex systems. He is among more than 200 researchers at UB using AI to address societal challenges. Also in June, more than 300 scholars from the Association for the Advancement of Artificial Intelligence, one of the world’s most recognized scientific organizations dedicated to advancing AI research, gathered at UB for a multiday conference. The scholars represented more than a dozen fields – including machine learning, psychology, political science, the humanities and more. July On July 17, SUNY Chancellor John B. King Jr. and state lawmakers visited UB for a roundtable discussion on AI. The attendees learned about UB researchers using AI to identify “forever chemicals,” as well as spinoff companies working on technology to improve treatment for strokes and aneurysms. “We are pioneering AI discoveries that will drive progress in research and economic development, demonstrating UB’s commitment to leveraging technology for societal benefit,” Govindaraju said. August The start of the new semester brought record enrollment to UB’s Master of Science program focusing on AI. Launched in 2020 with five students, the number swelled to 73 students this fall, with an additional 50 expected next semester. The program’s growth “shows that we’re providing students with in-demand skills that they can use for the betterment of society,” said Kemper E. Lewis, dean of the School of Engineering and Applied Sciences. Graduates have taken jobs at Amazon Web Services, NVIDIA, Visa and other companies. September UB was awarded $10 million from the U.S. Department of Education to establish the Center for Early Literacy and Responsible AI. The center will create AI tools to ensure culturally and linguistically diverse learners in grades K-2, including those in Western New York, receive transformative early literacy instruction. “We believe that, with the right support, all students — regardless of their backgrounds — can succeed in literacy,” says project leader X. Christine Wang, a professor of learning and instruction in the Graduate School of Education. Later in the month, Rep. Tim Kennedy announced UB would receive $475,000 to equip its wind tunnel with equipment that allows it to leverage the power of AI, among other technologies. UB uses the facility to study and improve the nation’s response to hurricanes, wildfires and other extreme weather. October On Oct. 11, roughly nine months after it was announced, Empire AI went live. Gov. Kathy Hochul flipped the switch on a stack of powerful new computer servers at Center of Excellence in Bioinformatics and Life Sciences. The servers represent a fraction of the eventual power of Empire AI, which will be located at a new building on North Campus. On the same day, UB President Satish K. Tripathi delivered his annual State of the University address. “While today, only the private sector has the computing power needed to seriously advance AI research, Empire AI will put New York State at the epicenter of artificial intelligence innovation. This game-changing initiative will enable us to tap the full power of AI to solve complex issues facing our state, nation and world.” November From fake celebrity endorsements to manipulated videos of politicians, the 2024 election was rife with misleading information. Debunking much of this content was the DeepFake-o-Meter, a publicly available tool used by journalists, law enforcement and others. The tool was created by UB computer scientist Siwei Lyu and students. With AI being added to medical devices, the Food and Drug Administration wants to ensure these products meet public health standards. The agency called upon experts, including UB’s Peter Elkin, for insight at a public meeting. Elkin, professor and chair of the Department of Bioinformatics, said the FDA should allow these devices to learn and therefore improve. “AI-enabled devices are no longer just tools; now they are partners in care,” he said. Back on campus, UB hosted the latest in a series of “AI at UB” forums on Nov. 21. Organizers updated faculty and staff on how UB is implementing AI in its classrooms and labs. Presenters also discussed how AI can be a tool to foster collaboration and enhance learning outcomes. December In early December, UB officials detailed plans to create a new academic department focused on AI and its impact on society. The department aligns with the mission of UB and SUNY, both of which are committed to responsibly harnessing the power of AI for social good. Around the same time, UB computer scientist Nalini Ratha published a series of research papers focused on machine learning and encrypted data. One of the papers suggests a new technique for safeguarding personal medical data as it travels from third-party cloud service providers back to patients and their doctors. The work points to a future where medical diagnostics are quicker and more accurate, and patient medical records remain confidential.There are also financial considerations to take into account. Messi commands a hefty salary and joining him would undoubtedly put a strain on Barcelona's already stretched budget. The club has been grappling with significant financial challenges in recent years, exacerbated by the economic impact of the COVID-19 pandemic. Bringing back Messi would require a significant financial commitment that could potentially limit the club's ability to invest in other areas, such as strengthening the defense or midfield.

Moderate Libs blame voters for their own failings

WELLINGTON, New Zealand, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Xcoub, a rising star in the decentralized finance (DeFi) staking space, has successfully closed a $7 million Series A funding round. Although the investors remain undisclosed, this significant investment highlights the growing confidence in Xcoub's ability to revolutionize the staking ecosystem. Renowned for its state-of-the-art technology, multi-chain compatibility, and user-centric design, Xcoub is quickly establishing itself as the go-to platform for secure and flexible staking solutions worldwide. Driving Innovation in DeFi Staking At the core of Xcoub's success is its advanced multi-chain staking platform, supporting over 10 leading blockchain networks, including Ethereum (ETH), Aptos (APT), and Optimism (OP). Xcoub's diverse staking options empower users to maximize returns while effectively managing risks, making it an ideal choice for both beginners and experienced investors. The platform is constantly evolving, introducing intuitive features that streamline the staking process and cater to both retail and institutional users. With a robust roadmap centered on technological growth and user satisfaction, Xcoub is paving the way for the next era in DeFi staking. Security First: The Bug Bounty Program Xcoub has launched a comprehensive Bug Bounty Program, offering up to $100,000 in rewards for identifying potential platform vulnerabilities. This proactive initiative fosters collaboration with global developers and security experts, ensuring the platform maintains top-tier security and reliability. By prioritizing user asset safety, Xcoub builds trust and sets a high standard for security in the DeFi space. Scaling Globally and Setting New Standards Armed with $7 million in Series A funding, Xcoub plans to expand its global reach, strengthen its presence in key markets, and grow its community of users. The funds will fuel infrastructure upgrades, the introduction of new features, and scaling efforts to meet the demands of DeFi enthusiasts worldwide. By focusing on scalability, innovation, and user empowerment, Xcoub is poised to set new benchmarks for DeFi staking. Its commitment to delivering high-performance, secure, and user-friendly staking solutions makes it a key player in the evolving decentralized finance landscape. A Vision for the Future As a pioneer in decentralized finance, Xcoub envisions a future where staking is accessible, secure, and profitable for everyone. Through continuous innovation and a focus on simplifying complex processes, Xcoub is ready to lead the next wave of DeFi evolution. Its dedication to addressing user challenges positions the platform as a transformative force in the industry. About Xcoub Xcoub is a decentralized finance (DeFi) staking platform built to simplify and elevate the staking experience for users worldwide. Supporting over 10 major blockchain networks, Xcoub offers secure, flexible, and high-yield staking opportunities. With a focus on innovation, user experience, and security, Xcoub is redefining DeFi staking and setting new standards for the industry. Xcoub Dapp: Xcoub.com Media Contact: Name: Eric Smith, Xcoub Finance Website: https://xcoub.com/ Email: [email protected] Disclaimer: This content is provided by Xcoub Finance . The statements, views and opinions expressed in this column are solely those of the content provider. The information provided in this press release is not a solicitation for investment, nor is it intended as investment advice, financial advice, or trading advice. It is strongly recommended you practice due diligence, including consultation with a professional financial advisor, before investing in or trading cryptocurrency and securities. Please conduct your own research and invest at your own risk. Photos accompanying this announcement are available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5b57ed6e-4d4f-4ec1-b668-af9b68d563fa https://www.globenewswire.com/NewsRoom/AttachmentNg/8556f13d-4808-4be5-bea1-0643a9572c41 https://www.globenewswire.com/NewsRoom/AttachmentNg/24cc26e8-be06-4113-b2d6-cede8e5478ae https://www.globenewswire.com/NewsRoom/AttachmentNg/28fc6951-66b1-469a-8f3b-410c2a8220beVancouver Whitecaps seek new ownershipIn conclusion, the 2021 ARRC season finale was a memorable event that saw Honda rider emerge victorious in the Superbike class. The championship win was a well-deserved reward for the rider's hard work and dedication throughout the season. As the ARRC looks towards the future, fans can eagerly anticipate more thrilling races, intense battles, and unforgettable moments on the track.